Consumer Medicine Information (CMI)
In mid-1991 Professor Peter Baume, in his report A Question of Balance: The Future of Drug Evaluation in Australia, recommended that a patient information document be developed for all prescription medicines. The first CMIs for prescription medicines became available in 1993.
In 1995, the legal requirement for CMIs was extended to Pharmacist-Only Medicines (Schedule 3). The TGA’s OTC Medicines Sections may also occasionally require CMI for other OTC products.
All CMIs, regardless of schedule, must be based on and consistent with the Product Information (PI) and must not be promotional.
Pharmacist-Only medicine CMIs must include the information specified in Schedule 13 of the Therapeutic Goods Regulations.
To make sure the information can be easily read and understood, CMI writers are encouraged to:
- make use of the publication Writing about Medicines for People: Usability Guidelines for Consumer Medicine Information (Usability Guidelines), which provides procedures for setting out, writing, testing, implementing and monitoring CMIs; and
- use the templates or “core” CMIs that have been developed for some therapeutic categories (see list below).
The CMI Content/Quality Assurance Reference Group was established in 1995 to oversee the provision of advice to sponsors concerning the development of CMIs and to assess CMIs to determine their quality and consistency with the Therapeutic Goods Regulations. Various stakeholder groups are represented on the Reference Group including consumers, doctors, pharmacists, nurses, pharmacologists, industry, CMI writers and communication experts.
The Reference Group can be contacted through its chair, Deborah Monk on (02) 6282 6888 or Project Officer, Mary Emanuel on (02) 9923 9407.
CMI Documents
Consumer Friendly Vocabulary for Medicine Information
Explanatory Note on the Vocabulary
Usability Guidelines
Principles about writing CMIs
The following core CMIs are available:
- Ace Inhibitors
- Anti-anginals
- Anti-convulsants
- Anti-depressants
- Antihistamines
- Anti-psychotics
- Antineoplastic (hormonal) agents
- Asthma – inhalational
- Asthma – oral
- Benzodiazepines
- Beta Blockers
- Cephalosporin antibiotics
- Diuretics
- Gastro-intestinal medicines to treat hyperacidity, reflux and ulcers
- General (generic)
- Glaucoma
- Human insulin injectables
- Hypoglycaemics -oral
- Hypolipidaemics (cholesterol lowering agents):
- Injectable vaccines for adults
- Injectable vaccines for both adult and paediatric use
- Injectable vaccines for paediatric use
- Intranasal corticosteroids
- Macrolide antibiotics
- Methotrexate
- Nitroimidazole antibiotics
- NSAIDs
- Oral vaccines for both adult and paediatric use
- Penicillin antibiotics
- Quinolone antibiotics
- Tetracycline antibiotics
- Topical corticosteroids
Analgesics containing codeine
CMIs
- Aspirin-Codeine Core CMI - FINAL Jan 2010
- Ibuprofen-Codeine Core CMI - FINAL Jan 2010
- Paracetamol-Codeine Core CMI - FINAL Jan 2010
PIs
- Aspirin-Codeine Core PI - FINAL Jan 2010
- Ibuprofen-Codeine Core PI - FINAL Jan 2010
- Paracetamol-Codeine Core PI - FINAL Jan 2010
Pseudoephedrine containing products
CMIs
- Bromhexine core CMI - FINAL 301105
- Codeine core CMI- FINAL 301105
- Dextromethorphan core CMI -FINAL 301105
- Guaiphenesin core CMI -FINAL 301105
- Ibuprofen core CMI- FINAL 301105
- Paracetamol core CMI -FINAL 301105
- Pholcodine core CMI -FINAL 301105
- Pseudoephedrine core CMI-FINAL 301105
- Sedating antihistamines core CMI -FINAL 301105
PIs
- Bromhexine Product Information -FINAL 301105
- Codeine Product Information -FINAL 301105
- Dextromethorphan Product Information -FINAL 301105
- Guaiphenesin Product Information -FINAL 301105
- Ibuprofen Product Information -FINAL 301105
- Paracetamol Product Information -FINAL 301105
- Pholcodine Product Information-FINAL 301105
- Pseudoephedrine Product Information -FINAL 301105
- Sedating Antihistamine PI -FINAL 301105
- Guidance for sponsors 301105.rtf
- PI Template Compilation Instructions 301105
- CMI Template Compilation Instructions 301105
If you require an editable Word version of any of the above Core CMIs, please contact Mary Emanuel on 02 9923 9407.